Onkologie. 2010:4(3):185-188
New mechanism of action in the treatment of renal cell carcinoma: m-TOR - a novel target
- 1 Onkologická klinika, FN a LF UP Olomouc
- 2 Klinika onkologie a radioterapie, FN Hradec Králové
PI3K/Akt/mTOR is a crucial signal transduction pathway taking part in the process of cancerogenesis as well as a target for anticancer
therapy. Inhibition of this pathway has become a promising target for cancer research, since alterations at distinct points of this signal
transduction pathway have been observed in multiple cancer types. HIF-alpha over-expression, typical for renal cell carcinoma, leads to
accumulation of proangiogenic factors and angiogenesis induction. Currently, there are 2 approaches of anticancer management using
different mechanisms of action: anti-VEGF (R) therapy, targeting mostly tumour angiogenesis, and mTOR inhibitors that exhibit a direct
anti-tumour effect leading to cell cycle arrest in G1 phase and apoptosis induction.
Keywords: mTOR, mTOR inhibition, HIF-alpha, VEGF (R) targeted therapy
Published: July 1, 2010 Show citation
References
- Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18(16): 1926-1945.
Go to original source... 
Go to PubMed... - Noh WC, Mondesire WH, Peng J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004; 10(3): 249-258. Go to original source... Go to PubMed...
- Oshiro N, Yoshino K, Hidaya S, et al. Dissociation of raptro from mTOR is a mechanism of ramapycin-induced inhibition of mTOR function. Genes Cells 2004; 9(4): 359-366. Go to original source... Go to PubMed...
- Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22: 4991-5004. Go to original source... Go to PubMed...
- Kondo K, Yao M, Yoshida M, et al. Comprehensive mutanional analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parametres. Genes Chromosomes Cancer 2002; 34: 58-68. Go to original source... Go to PubMed...
- Rini BI. Metastatic Renal Cell Carcinoma: Many treatment options, One Patient. J Clin Oncol 2009; 19: 3225-3234. Go to original source... Go to PubMed...
- Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr. TSC2 regulates VEGF through mTOR-dependent and independent pathways. Cancer Cell 2003; 4: 147-158. Go to original source... Go to PubMed...
- Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006; 12: 122-127. Go to original source... Go to PubMed...
- Bergers G, Hanahan D. Modes of resistance to ani-angiogenic therapy. Nature 2008: 592-603. Go to original source... Go to PubMed...
- Meric-Bernstam F, Gonzales-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009; 27: 2278-2287. Go to original source... Go to PubMed...
- Lane HA, Wood JM, McSheehy PM, et al. MTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009; 15: 1612-1622. Go to original source... Go to PubMed...
- Edinger AL, Linardic CM, Chiang GG, Thompson CB, Abraham RT. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res 2003; 63: 8451-8460.
- Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307(5712): 1098-1101. Go to original source... Go to PubMed...